Protein and gene levels of DNAJC21 and RNF5 as drug targets for immune thrombocytopenia: optimized post-GWAS insights [0.03%]
DNAJC21和RNF5的蛋白及基因水平作为免疫性血小板减少症的药物靶点：优化后的GWAS后发现
Xiaoli Li,Jun Li,Yang Lan et al.
Xiaoli Li et al.
Objectives: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by antibody-mediated platelet (PLT) destruction. Its clinical manifestations are highly heterogeneous, and the unclear pathogenesis poses s...
Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025 [0.03%]
2025年比利时专家小组关于三线及以后治疗慢性髓系白血病慢性期患者的建议
Peter Vandenberghe,Dominiek Mazure,Gaëlle Vertenoeil et al.
Peter Vandenberghe et al.
Introduction: Tyrosine kinase inhibitors (TKIs) have revolutionized the therapy of chronic myeloid leukemia (CML) in chronic phase, opening up the perspective of a normal life expectancy for most patients and of treatment...
NPM1 mediated up - regulation of CXCR4 might drive bortezomib resistance in multiple Myeloma [0.03%]
NPM1介导的CXCR4上调可能驱动硼替佐米引起的多发性骨髓瘤耐药性
Yuye Shi,Yuan Deng,Jingjing Ma et al.
Yuye Shi et al.
Objective: Bortezomib (BTZ) containing regimens induces significant antitumor response in multiple myeloma (MM) and are considered as the first-line treatment. However, resistance is still one of the unsolved problems. Th...
Sepsis and organ failure are the major risks for allogeneic transplant patients in the post- or late- engraftment phase admitted to the ICU [0.03%]
同种异体移植患者入住ICU时移植物抗宿主病后的主要风险为感染和器官功能衰竭
Michael Serries,Lisa Faßbender,Hannah Zenzen et al.
Michael Serries et al.
Objectives: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can lead to complications, depending on the period of the transplantation. Our study aimed to evaluate the outcome and prognostic parameters for t...
Epidemiological landscape of early-onset multiple myeloma: global burden, temporal trends, cross-country inequality, and projections to 2045 [0.03%]
早发多发性骨髓瘤的流行病学特征：全球负担、时间趋势、国家间差异及至2045年的预测分布
Hao Zhang,Ming Li,Long Zhao et al.
Hao Zhang et al.
Background: Early-onset multiple myeloma (MM), defined as being diagnosed before the age of 50, has become an increasing global concern. However, a systematic examination of the global epidemiological landscape of early-o...
Clinical use and safety of empiric anticoagulation during diagnostic work-up for deep vein thrombosis [0.03%]
诊断性检查期间经验性抗凝的临床应用及安全性：深静脉血栓形成患者的病例报告
Hodo Mohamad,Camilla Tøvik Jørgensen,Waleed Ghanima et al.
Hodo Mohamad et al.
Background: Previous studies suggest the safety of empiric anticoagulation administered to patients with suspected deep vein thrombosis (DVT) before the work-up is completed. However, the safety of such practice has not b...
In vitro antitumor effects of PI3K inhibitor linperlisib (YY-20394) on acute myeloid leukemia cells [0.03%]
PI3K抑制剂林贝利西(YY-20394)对急性髓系白血病细胞的体外抗肿瘤作用
Jia-Qi Chen,Yan Lou,Li-Li Zhou et al.
Jia-Qi Chen et al.
Objective: To investigate the effects of the PI3 K inhibitor, linperlisib (YY20394), on proliferation, apoptosis, cell cycle and signaling pathways in acute myeloid leukemia (AML) cells. ...
Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study [0.03%]
移植前血红蛋白、多发性骨髓瘤亚型和诱导方案均为自体干细胞移植后生存的独立预后因素：回顾性队列研究
Yong Zhang,Guangzhong Yang,Wen Gao et al.
Yong Zhang et al.
Background: Autologous hematopoietic stem cell transplantation (auto-HSCT) is standard for eligible multiple myeloma (MM) patients, yet outcomes are heterogeneous. Besides established markers like cytogenetics and ISS, th...
The efficacy of varying doses of venetoclax combined with azacitidine for newly diagnosed adult acute myeloid leukemia in real-world settings: a single-center retrospective analysis [0.03%]
不同剂量的维奈克拉联合地西他滨治疗新诊断成人急性髓系白血病的真实世界疗效：一项单中心回顾分析
Yanjie Mao,Yifeng Cai,Yanan Wu et al.
Yanjie Mao et al.
Introduction: The combination of venetoclax and azacitidine shows significant efficacy in newly diagnosed acute myeloid leukemia (ndAML) patients. In specific contexts, low-dose venetoclax may be preferred to optimize pat...
The prognostic impact of chromosome 7 with both arms loss [der(7)del(7p)del(7q)] in myelodysplastic syndrome/neoplasm [0.03%]
染色体7双臂缺失[der(7) del(7p)/del(7q)]对骨髓增生异常综合症/肿瘤预后的影响
Ji Zhou,Linlin Liu,Chenghua Cui et al.
Ji Zhou et al.
Objectives: Chromosome 7 abnormality characterized by loss of both arms [der(7)del(7p)del(7q), hereafter 'der(7)'] is very rare. The features and prognosis of patients with der(7) in myelodysplastic syndromes (MDS) remain...